Navigation Links
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
Date:5/14/2009

ntation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 97738057.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this pr
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon reports first quarter 2009 financial results
2. YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
3. Transgenomic, Inc. Reports First Quarter 2009 Results
4. Insmed Announces First Quarter 2009 Financial Results
5. BioMS Medical Announces First quarter 2009 results
6. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
7. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
8. deCODE genetics Announces First Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
11. VIVUS Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... This release from ... -- or even whether -- invasive saltcedar should be controlled. The Society contends that ... and carefully weigh the impact of our decisions. , ... Lawrence, KS (PRWEB) August 24, 2009 -- Saltcedar (Tamarix spp.) is ...
... LEIDEN, The Netherlands and SEATTLE, August ... innovative products for hemostasis and,regenerative medicine, today announced the ... The financing round was led by new investor,Gilde Healthcare ... investor Index Ventures. Dirk Kersten from Gilde will join ...
... , SEATTLE, Aug. 21 Cell ... closing of its previously announced sale of $30 million of shares ... of its common stock in a registered offering to a single ... its shares of Series 2 Preferred Stock and to receive the ...
Cached Biology Technology:Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 2Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 3ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing 2ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing 3Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants 2
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... BioScience includes the following peer-reviewed articles: Molecular ... Patrick J. Tranel and David P. Horvath. , Modern ... development of herbicide-resistant crops and a better understanding of ... of tools, including genomics, could yield novel and still ...
... system response that is critical to the first stages ... an entirely different direction than most scientists had thought, ... University Medical Center. "This finding will have ... development," said Michael Gunn, M.D., an immunologist and cardiologist ...
... Christopher Fasano (Memorial Sloan-Kettering Cancer Center) and colleagues lend ... stem cells outside of the neurogenic niche. , ... Bmi-1, maintains forebrain neural stem cell self-renewal. Overexpression of ... increases stem cell self-renewal both in vitro and in ...
Cached Biology News:BioScience tip sheet, March 2009 2New origin found for a critical immune response 2
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Antibody is used to detect the appearance ... of infected cells as early as 8-24 ... the FastPlax Titer Kit, which allows determination ... The FastPlax Antibody can also ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
Biology Products: